The global hospital infection therapeutics market size accounted for USD 12.46 billion in 2024, grew to USD 12.82 billion in 2025 and is expected to be worth around USD 16.59 billion by 2034, registering a CAGR of 2.9% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Hospital Infection Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Hospital Infection Therapeutics Market, by Drug Type, 2024-2034
8.1.1. Antibiotics Drugs
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Antifungal Drugs
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Antiviral Drugs
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Hospital Infection Therapeutics Market, by February, 2024-2034
9.1.1. Bloodstream Infections
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Pneumonia
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Surgical Site Infections
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Urinary Tract Infections
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Gastrointestinal Disorders
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Other Hospital Infections
9.1.6.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.1.2. Market Revenue and Forecast, by February (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by February (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by February (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.2.2. Market Revenue and Forecast, by February (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by February (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by February (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by February (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by February (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.3.2. Market Revenue and Forecast, by February (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by February (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by February (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by February (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by February (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.4.2. Market Revenue and Forecast, by February (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by February (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by February (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by February (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by February (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.5.2. Market Revenue and Forecast, by February (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by February (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by February (2021-2034)
11.1. Merck & Co., Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pfizer Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Bayer AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. GlaxoSmithKline Plc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Daiichi Sankyo Company, Limited
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. AbbVie Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Abbott Laboratories
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. F. Hoffmann-La Roche Ltd
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Allergan Plc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. AstraZeneca
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample